Loading
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$39.18
+$0.05 · +0.13%
Previous close
$39.18
+$0.05 · +0.13%
Pre-market
$38.82
−$0.36 · -0.92%
Oct 8, 4:56 AM ET
Regular session · ET · Market data may be delayed.
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Day range
Current $39.18
52-week range
Current $39.18
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
81
Deep Value
Sentiment
74
Bullish
Risk
33
Moderate Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Day range
Current $39.18
52-week range
Current $39.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.26B USD | 16.54B USD | 15.85B USD | 14.93B USD | 15.88B USD |
| Cost of goods sold | 8.32B USD | 8.48B USD | 8.2B USD | 7.95B USD | 8.28B USD |
| Gross profit | 8.94B USD | 8.06B USD | 7.65B USD | 6.97B USD | 7.59B USD |
| Research and development | 1.01B USD | 1.06B USD | 953M USD | 838M USD | 1.09B USD |
| Selling, general, and administrative | 3.97B USD | 3.7B USD | 3.5B USD | 3.45B USD | 3.53B USD |
| Operating expenses | 6.78B USD | 8.37B USD | 7.21B USD | 9.17B USD | 5.88B USD |
| Interest income | — | — | 68M USD | — | — |
| Interest expense | 916M USD | 941M USD | 1.03B USD | 930M USD | 891M USD |
| Depreciation and amortization | 1B USD | 1.06B USD | 1.15B USD | 1.31B USD | 1.33B USD |
| Operating income | 2.16B USD | −303M USD | 433M USD | −2.2B USD | 1.72B USD |
| Net income | 1.41B USD | −1.64B USD | −559M USD | −2.45B USD | 417M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$45.80
16.90% upsideCash distributions grouped by calendar year; partial years are marked.
$0.85
2017 complete year-33.5% since 2013
$1.278
2,013
$1.366
2,014
$1.36
2,015
$1.36
2,016
$0.85
2,017
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Nov 27, 2017 | $0.085Quarterly | Nov 28, 2017 | Dec 12, 2017 |
Dividend | Aug 25, 2017 | $0.085Quarterly | Aug 29, 2017 | Sep 14, 2017 |
Dividend | Jun 1, 2017 | $0.34Quarterly | Jun 5, 2017 | Jun 22, 2017 |
Dividend | Feb 28, 2017 | $0.34Quarterly | Mar 2, 2017 | Mar 20, 2017 |
Dividend | Dec 1, 2016 | $0.34Quarterly | Dec 5, 2016 | Dec 20, 2016 |
Dividend | Aug 18, 2016 | $0.34Quarterly | Aug 22, 2016 | Sep 8, 2016 |
Ex-dividend Nov 27, 2017
$0.085
Quarterly
Record Nov 28, 2017 · Payment Dec 12, 2017
Ex-dividend Aug 25, 2017
$0.085
Quarterly
Record Aug 29, 2017 · Payment Sep 14, 2017
Ex-dividend Jun 1, 2017
$0.34
Quarterly
Record Jun 5, 2017 · Payment Jun 22, 2017
Ex-dividend Feb 28, 2017
$0.34
Quarterly
Record Mar 2, 2017 · Payment Mar 20, 2017
Ex-dividend Dec 1, 2016
$0.34
Quarterly
Record Dec 5, 2016 · Payment Dec 20, 2016
Ex-dividend Aug 18, 2016
$0.34
Quarterly
Record Aug 22, 2016 · Payment Sep 8, 2016
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI EAFE ETFIEFA346.47M0.18%191.47B USD0.07%$96.20-1.08%
iShares MSCI EAFE ETFEFA163.53M0.21%77.37B USD0.32%$103.1-1.07%
Schwab International Equity ETFSCHF104.86M0.16%68.57B USD0.03%$27.26-1.23%
iShares MSCI Israel ETFEIS98.11M11.19%876.03M USD0.59%$117.95-1.90%
First Trust WCM International Equity ETFWCMI75.65M3.57%2.12B USD0.85%$18.99-1.58%
iShares MSCI EAFE Growth ETFEFG64.74M0.42%15.22B USD0.34%$119.69-1.18%
iShares Core MSCI Total International Stock ETFIXUS63.01M0.11%59.46B USD0.07%$94.90-1.21%
iShares Core MSCI International Developed Markets ETFIDEV54.35M0.16%33.18B USD0.04%$88.79-1.19%iShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE ETFEFASchwab International Equity ETFSCHFiShares MSCI Israel ETFEISFirst Trust WCM International Equity ETFWCMIiShares MSCI EAFE Growth ETFEFGiShares Core MSCI Total International Stock ETFIXUSiShares Core MSCI International Developed Markets ETFIDEVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
